Hypertension and Gout: A Package Deal

For the answer, click here.

Question 2:

A 76-year-old man who has had many prior nonmelanoma skin cancers and one melanoma in situ now has an asymptomatic lesion on his ankle.

NEXT QUESTION »

For the answer, click here.

Question 3:

NEXT QUESTION »

For the answer, click here.

Question 4:

Large plaque parapsoriasis was diagnosed in a 66-year-old woman.

NEXT QUESTION »

For the answer, click here.

Question 5:

A 40-year-old man had a severely painful bump on his ear. He has no history of skin cancer.

ANSWER KEY »

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

ANSWER KEY:

Question 1. A

Question 2. C

Question 3. A

Question 4. E

Question 5. B

Related Content

Patient Care Staff

January 17th 2025

Primary Viewpoints Episode 3: The Challenges of Hypertension Management

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

Smartphone App Shows Promise for Managing Hypertension in Observational Study

September 30th 2020

Podcast

In episode 3 of Primary Viewpoints, Brigham and Women's hypertension expert Naomi Deirdre Fisher, MD, discusses the challenges of hypertension management in primary care.

December 20th 2024

Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes

People with hypertension who adhered to the mobile app demonstrated well-controlled blood pressure over a 12-week observational period.

Podcast: Hypertension expert Daichi Shimbo, MD, offers tips on putting SPRINT results into clinical practice.

Grace Halsey

November 18th 2024

Aprocitentan Now Available in the US for Treatment-Resistant Hypertension

AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.

November 15th 2024

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

Aprocitentan is the first-and-only dual endothelin receptor antagonist approved for the treatment of systemic hypertension.

Related Content

Patient Care Staff

January 17th 2025

Primary Viewpoints Episode 3: The Challenges of Hypertension Management

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

Smartphone App Shows Promise for Managing Hypertension in Observational Study

September 30th 2020

Podcast

In episode 3 of Primary Viewpoints, Brigham and Women's hypertension expert Naomi Deirdre Fisher, MD, discusses the challenges of hypertension management in primary care.

December 20th 2024

Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes

People with hypertension who adhered to the mobile app demonstrated well-controlled blood pressure over a 12-week observational period.

Podcast: Hypertension expert Daichi Shimbo, MD, offers tips on putting SPRINT results into clinical practice.

Grace Halsey

November 18th 2024

Aprocitentan Now Available in the US for Treatment-Resistant Hypertension

AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.

November 15th 2024